Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desmopressin
Drug ID BADD_D00616
Description Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney [T28]. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH [A31661]. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate [A31662]. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate. Nocdurna, or desmopressin acetate, was approved by the FDA on June 21st, 2018 for the treatment of nocturia due to nocturnal polyuria in adults. It is available as a sublingual tablet.
Indications and Usage - Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to m
Marketing Status Prescription; Discontinued
ATC Code H01BA02
DrugBank ID DB00035
KEGG ID D00291
MeSH ID D003894
PubChem ID 5311065
TTD Drug ID D0U7SH
NDC Product Code 52416-115; 41701-007; 62938-0023; 52416-108; 60870-0440; 62938-0024
Synonyms Deamino Arginine Vasopressin | Arginine Vasopressin, Deamino | 1-Desamino-8-arginine Vasopressin | Vasopressin, 1-Desamino-8-arginine | Desmopressin | Vasopressin, Deamino Arginine | 1-Deamino-8-D-arginine Vasopressin | Vasopressin, 1-Deamino-8-D-arginine | Adiuretin SD | Apo-Desmopressin | DDAVP | Octostim | Desmotabs | Octim | Desmopressine Ferring | Ferring, Desmopressine | Desmospray | Nocutil | Desmopressin Acetate | Acetate, Desmopressin | Desmopressin Monoacetate, Trihydrate | Monoacetate, Trihydrate Desmopressin | Trihydrate Desmopressin Monoacetate | Desmopressin Monoacetate | Monoacetate, Desmopressin | Minirin | Minurin | Adiuretin | Desmogalen
Chemical Information
Molecular Formula C46H64N14O12S2
CAS Registry Number 16679-58-6
SMILES C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)C C3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ThrombophlebitisProtein kinase C delta typeQ05655T448613840287; 2363094; 8800154; 2146406
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oropharyngeal discomfort07.05.05.008; 22.02.05.027--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Osmotic demyelination syndrome17.16.02.0040.005881%Not Available
Langerhans' cell histiocytosis22.01.01.016; 16.21.04.003; 15.09.03.008; 01.13.04.0030.005881%Not Available
Hyponatraemic encephalopathy17.13.01.011; 14.05.04.0070.002557%Not Available
Hyponatraemic seizure17.12.03.025; 14.05.04.0080.003921%Not Available
The 7th Page    First    Pre   7    Total 7 Pages